Norgine launches Setofilm in the United Kingdom for the prevention of Nausea
Norgine B.V. has announced the launch in the United Kingdom of Setofilm an orally dispersible film (ODF) formulation of ondansetron. Setofilm is the first prescription product developed as an ODF formulation to be registered in Europe.
Setofilm is indicated for the prevention and treatment of Chemotherapy Induced Nausea and Vomiting (�CINV�) in adults as well as children aged 6 months or above, Radiotherapy Induced Nausea and Vomiting (�RINV�) in adults and the prevention and treatment of Post-Operative Nausea and Vomiting (PONV) in adults and children aged 4 years or above.
Norgine B.V. has acquired the commercialization rights in Europe and selected non-European countries in Middle East, Africa and Australasia.
Ondansetron ODF formulation is approved in the US and marketed there as Zuplenz by Vestiq Pharma.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins